STO-CSCO Joint Symposium - 2016

Harnessing Big Data for Precision Medicine

Xiamen International Conference & Exhibition Center
Xiamen International Conference & Exhibition Center

September 23, 2016
Xiamen International Conference and Exhibition Center
Xiamen, China

Continuing to build on the vibrant partnership of STO and CSCO, the Second Annual STO-CSCO Joint Symposium will be featured during the 19th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) on September 23, 2016.

Our inaugural theme focused on the impact of big data on cancer research and cancer patients. In our second year, we expand our focus to include strategies for Harnessing Big Data for Precision Medicine.

Symposium Co-Chairmen

Professor Shukui QIN, MD
Beijing Xisike Clinical Oncology
Research Foundation

Professor Martin J. Murphy,
Convener, STO
Chief Executive Officer,
CEO Roundtable on Cancer



Platform Strategy in Big Data Era
Yasong WANG

General Manager, GuoXin YoueData Co. Ltd.
Director, Data Operation Department, State Information Center
Master of Arts, Sheffield Hallam University, Britain

Opportunities and Challenges in Big Data Era of Medicine
James C. Gee, PhD

University of Pennsylvania, USA
University of Electronic Science and Technology of China

Alliance Experience with Data Curation and Aggregation
Jiping WANG, MD, PhD

Brigham and Women's Hospital, Harvard Medical School
Gastrointestinal Cancer Treatment Center, Dana-Farber Cancer Institute

When is a Single Arm Trial Allowed for Review?
Olivier Collignon, PhD

Biostatistician, Seconded National Expert, EMA

Applications of Aggregated Data and the Analysis of Clinical Trials
James Xunhai XU, MD

Medical Officer, GU Team, U.S. FDA

“What is the value of your clinical data in the era of Precision Medicine & Big Data?”
Moderated by Professor QIN & Professor Murphy, Co-Chairmen

Memorandum of Understanding Signing
Between Chinese Society of Clinical Oncology (CSCO) and Society for Translation Oncology (STO)

Faculty Biographies

Prof. Shukui QIN

Director, PLA Cancer Center & Vice-President, Nanjing Bayi Hospital
Vice President, CSCO

President, Beijing Xisike Clinical Oncology Research Foundation
Prof. QIN has engaged in oncology clinical and research work for a long time, specializing in the diagnosis and treatment of digestive system tumors and clinical research. He has authored more than 580 scientific papers and 60 monographs. He has received numerous professional awards, including first and second prizes of the National Scientific and Technological Progress Award and multiple provincial science and technology awards.

Martin J. Murphy, DMedSc, PhD, FASCO

As co-founder of the Society for Translational Oncology (Richard M. Goldberg & Patrick G. Johnston, co-chairs), he is a member of the Scientific Advisory Board of Hatteras Venture Partners (Herbert Boyer, chair), a charter member of the International Advisory Board of the VU University Medical Imaging Center, a charter member of Queen’s University-Belfast School of Medicine International Review Board, Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), and Steering Committee Member and Senior Consultant of the Chinese Society of Clinical Oncology (CSCO). Dr. Martin J. Murphy is Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc., which provides strategic support for cancer drug development programs of academic centers, global pharmaceutical and biotechnology companies. Co-Founder with Dr. Ann Murphy of AlphaMed Press, Dr. Murphy is also the Founding Executive Editor of the 21-year-old peer-reviewed journal, The Oncologist (Bruce A. Chabner, Editor-in-Chief); he is also the Founding Executive Editor of both Stem Cells (Jan Nolta, Editor-in-Chief), a 34-year-old journal of stem cell biology, and of the 5-year-old journal, Stem Cells Translational Medicine (Anthony Atala, Editor-in-Chief).

Dr. Murphy was founder and former CEO of the Hipple Cancer Research Center, NIH principal investigator and authored more than 150 peer-reviewed papers.

Yasong WANG

General Manager, GuoXin YoueData Co. Ltd
Director of Data Operation Department, State Information Center
Member of Expert Committee, Ecological Alliance of China Big Data Industry

Mr. WANG is a representative of innovation in the China big data industry, with 10 years of experience in business, project, and market management. In just 1 year under his leadership, GuoXin YoueData Co. Ltd. grew and achieved considerable visibility and recognition in the industry. He proposed the “Double Innovation Index,” which was highlighted at the 2016 Chengdu Global Innovation and Entrepreneurship Fair. Through the establishment of a large data trading platform, he developed the national data center, creating a data distribution network with joint large data exchange among data centers, financial institutions, and trade centers to promote the innovation of large data trading patterns.

James C. Gee, PhD

One-thousand-talent plan distinguished professor
Professor, University of Pennsylvania, USA
Professor, University of Electronic Science and Technology of China

Dr. Gee’s research interests focus on computational medicine. He has published more than 200 peer-reviewed articles in computational medicine. He has served on the editorial boards of IEEE TBME, IEEE TMI, and NeuroImage. He received the ARR Investigator award in 2013. As one of the world’s foremost experts in biomedical image computing, his widely recognized contributions have been in diverse fields, including computational anatomy, diffusion magnetic resonance imaging, biomedical image analysis, and medical data science.

Jiping Wang, MD, PhD

Division of Surgical Oncology at Brigham and Women’s Hospital, Harvard Medical School
Gastrointestinal Cancer Treatment Center at Dana-Farber Cancer Institute

Dr. Wang practices oncologic surgery with the focus on minimally invasive cancer surgery for gastrointestinal malignancies, including liver cancer, colorectal cancer liver metastasis, pancreatic, gastric, colorectal cancer and neuroendocrine tumors. He received his PhD training in Biostatistics at the University of Pittsburgh. He served as a biostatistician at the National Surgical Adjuvant Breast and Bowel Project, where he participated in multiple phase III breast cancer clinical trials upon his graduation. Subsequently, Dr. Wang obtained the Fineberg Fellowship training at Brigham and Women’s Hospital, Massachusetts General Hospital and Dana-Farber Cancer Institute after his general surgery resident training.

Dr. Wang’s research focuses on identification of tumor markers for cancer screening, monitoring treatment effect and prognosis, development of algorithms and/or scoring systems to guide clinical oncology research and practice, and clinical trials for cancer prevention and treatment. Dr. Wang has been involving in clinical research on breast and GI cancer for over 10 years. His research in oncology has received many national level awards, including ASCO Annual Meeting Merit Award (2008, 2010), ASCO Breast Cancer Symposium Merit Award (2007), Seed Grant from American Medical Association Foundation (2008), and AstraZeneca Scholar (2002). He also won the Leadership Scholarship from American College of Surgeons (ACS) 2008 and the scholarship from ASCO/AACR (2009). Dr. Wang serves as the committee member for multiple surgical societies, including the American College of Surgeons and the Society for Surgery of the Alimentary Tract.

Olivier Collignon, PhD

Biostatistician, Seconded National Expert
European Medicines Agency, London, United Kingdom
Luxembourg Institute of Health, Strassen, Luxembourg

Dr. Olivier Collignon is statistics consultant for researchers at LIH and external groups. He is currently seconded at the European Medicines Agency in London, where he scientifically evaluates the design and results of clinical trials to obtain marketing authorization of new drugs in Europe. He is especially interested in adaptive designs and the use of historical controls. His expertise also consists in developing variable selection algorithms and supervised classification methods to help biologists find new biomarkers and risk factors of different diseases, especially in cardiology. Dr. Collignon started a joint effort with the University of Seoul and with the Netherlands Cancer Institute to develop a new variable selection method that is being validated on breast cancer biomarkers. Dr. Collignon is involved in the National Cancer Registry of Luxembourg, for which he is in charge of data analysis for epidemiologic studies. He is also involved in various teaching activities.

James Xunhai Xu, MD

Medical Officer, GU Team, U.S. FDA

Dr. James Xunhai Xu is a medical officer with FDA/CDER/OND/OHOP’s genitourinary cancer products review team. He received his Bachelor of Science degree in chemical engineering with a minor in mathematics from Brigham Young University and his M.D. degree from the University of Minnesota. He completed his internal medicine residency at Yale-New Haven Hospital of Yale University in New Haven, CT, and his hematology and medical oncology fellowship at New York-Presbyterian Hospital of Columbia University in New York City.

Dr. Xu is the recipient of the ASCO (American Society of Clinical Oncology) Conquer Cancer Foundation Young Investigator Award in 2011 and Merit Award in 2012. Dr. Xu is the first to have proposed and preliminarily confirmed the feasibility of using voltage-based deep sequencing technology to detect genetic mutation in circulating tumor cells from patients’ peripheral blood. Dr. Xu is board certified in internal medicine, hematology, and medical oncology.